AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
Authors: I. Mcinnes, E. Soriano, L. S. Tam, N. Shiff, M. Shawi, E. Rampakakis, J. Curtis
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Patients (pts) with psoriatic arthritis (PsA) experience lower quality of life than both the general population and pts with psoriasis alone<sup>[1,2]</sup>. Recent PsA treatment recommendations highlight the importance of maximizing long-term (LT) health-related quality of life (HRQoL) and social participation as primary goals of therapy<sup>[3]</sup>. <h3>Objectives</h3> To determine whether early clinical improvement with guselkumab (GUS) predicts future attainment of enhanced HRQoL. <h3>Methods</h3> DISCOVER-2 enrolled adults naïve to biologics/JAK inhibitors who had active PsA defined as swollen joint count (SJC) ≥5, tender joint count (TJC) ≥5, and C-reactive protein (CRP) ≥0.6 mg/dL. 739 pts were randomized (1:1:1) and treated with GUS 100 mg every 4 weeks (Q4W; n=245); GUS 100 mg at W0, W4, then Q8W (n=248); or placebo (PBO) (n=246). In this post hoc analysis, pts treated with GUS Q4W and GUS Q8W were pooled. Early (W8) clinical improvement was defined as any of: (i) ≥20% improvement in SJC, TJC, pt pain, pt skin visual analog scale (VAS), and Health Assessment Questionnaire-Disability Index (HAQ-DI); (ii) ≥4-point improvement in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score; (iii) minimally clinically important improvement (MCII) in clinical disease activity in PsA (cDAPSA; ≥5.7 points); (iv) change in Leeds enthesitis index (LEI) and dactylitis severity score (DSS) at W8 among pts with baseline (BL) enthesitis and dactylitis, respectively. Time-averaged changes in HRQoL estimates from BL to W52-100 were determined for Dermatology Life Quality Index (DLQI), EQ-5D Index &amp; VAS, and SF-36 mental (MCS) and physical (PCS) component summary scores. The association between early clinical improvement at W8 and LT HRQoL among GUS-treated pts was assessed with mixed models. <h3>Results</h3> Clinical improvement by W8 was significantly greater among GUS-treated patients compared with PBO. Early clinical improvement with GUS was associated with greater increase in HRQoL (EQ-5D) at W52 through W100, with the exception of SJC on EQ-5D VAS (Figure 1; LEI &amp; DSS results not shown). Similarly, pts achieving early clinical improvement in any domain except DSS and SJC experienced significantly greater benefits in physical function (SF-36 PCS) at W52-W100. Early improvements in skin disease and fatigue were associated with greater improvement in mental health (SF-36 MCS) at W52-W100, while for skin-specific HRQoL (DLQI), early pt skin VAS response was the only predictor of HRQoL at W52-W100. Although significantly lower than in pts with early clinical improvement, benefits in HRQoL were also observed in pts without clinical improvement at W8. <h3>Conclusion</h3> Clinical response at W8 with GUS was associated with significantly greater improvements in HRQoL from W52 through W100. Although pts without early clinical improvement demonstrated benefits in LT HRQoL, early response in distinct PsA domains differentially impacted more specific aspects of HRQoL over 2 years. In contrast, significantly greater improvements in overall and physical HRQoL were observed among responders across several PsA domains. <h3>References</h3> [1]Michelsen B, et al. <i>Ann Rheum Dis</i>. 2018 Sep;77(9):1290-4. [2]Rosen CF, et al. <i>Rheumatology (Oxford</i>). 2012 Mar;51(3):571-6. [3]Coates LC, et al. <i>J Rheumatol</i>. 2022 Mar;jrheum.211331. <h3>Disclosure of Interests:</h3> Iain McInnes Consultant of: AbbVie, Amgen, Astra Zeneca, Bristol-Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB, Grant/research support from: Amgen, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder for Causeway Therapeutics, and Evelo Compugen, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Lai-Shan Tam Consultant of: AbbVie, AstraZenaca, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, and Sanofi, Grant/research support from: Amgen, Boehringer Ingelheim, GSK, Janssen, Novartis and Pfizer, Natalie Shiff Shareholder of: Johnson &amp; Johnson, AbbVie, and Gilead, Employee of: Janssen Scientific Affairs, LLC, May Shawi Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Jeffrey Curtis Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB.